Share This Page
Drug Price Trends for NDC 62135-0959
✉ Email this page to a colleague
Average Pharmacy Cost for 62135-0959
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| PHENTERMINE 8 MG TABLET | 62135-0959-90 | 0.61440 | EACH | 2025-12-24 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 62135-0959
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC 62135-0959
Executive Summary
This report provides a comprehensive market analysis and price projection for the drug identified by NDC 62135-0959. The drug, marketed under the brand name [Brand Name] (if applicable), is a [drug class or therapeutic category], primarily used in [indications]. This analysis synthesizes market size, competitive landscape, regulatory influences, pricing trends, and future demand forecasts based on current data, industry reports, and policy trends.
Key Highlights:
- Approximate market value: $[industry estimate] billion (2022)
- Expected Compound Annual Growth Rate (CAGR): [X]% (2023-2030)
- Predicted retail price range (2023): $[X] - $[Y]
- Anticipated market drivers: innovations in therapy, regulatory approvals, increasing prevalence of target conditions
- Potential challenges: pricing pressures, biosimilar competition, future patent expirations
What is NDC 62135-0959?
The National Drug Code (NDC) 62135-0959 pertains to [specific drug, formulation, and manufacturer details]. The NDC format indicates:
| Segment | Description |
|---|---|
| 62135 | Manufacturer/Distributor |
| 0959 | Specific product/strength/dose |
This drug is used in [specific therapeutic area], with typical indications including [diseases or conditions].
Market Overview
Therapeutic Area Analysis
| Aspect | Details |
|---|---|
| Drug Class | [e.g., monoclonal antibody, small molecule, biologic] |
| Primary Indications | [e.g., rheumatoid arthritis, oncology, diabetes] |
| Route of Administration | [e.g., IV, oral, SC] |
| Patent Status | [patent expiry date or exclusivity period] |
Market Size & Revenue Trends
- Global Market Value: Estimated at $[X] billion in 2022, with North America accounting for [Y]%.
- Market Growth Drivers: Rising prevalence of [target diseases], technological advances, approvals of expanded indications.
- Market Segmentation: Led by [specific regions or populations].
Competitive Landscape
| Brand Name | Manufacturer | Market Share | Price Point (approximate) | Key Differentiators |
|---|---|---|---|---|
| [Competitor 1] | [Company] | [X]% | $[amount] | [E.g., higher efficacy, lower side effects] |
| [Competitor 2] | [Company] | [Y]% | $[amount] | [E.g., extended dosing interval] |
| [Generic/Biosimilar] | [Company] | [Z]% | $[amount] | Cost-effective alternative |
Price Analysis and Trending Factors
Historical Pricing Trends
| Year | Average Wholesale Price (AWP) | Retail Price Range | Change (%) from Previous Year |
|---|---|---|---|
| 2020 | $[X] | $[Y] - $[Z] | [X]% |
| 2021 | $[X] | $[Y] - $[Z] | [Y]% |
| 2022 | $[X] | $[Y] - $[Z] | [Z]% |
Market-Driven Pricing Factors
- Regulatory Changes: FDA approvals, CMS reimbursement policies, and patent litigations influence pricing.
- Manufacturing Costs: Raw material prices, biologic manufacturing complexities.
- Market Competition: Biosimilars and generics eroding prices.
- Value-Based Pricing: Increased focus on therapeutic outcomes and patient adherence.
- Policy Changes: International pricing policies, import regulations, and Medicare/Medicaid pricing standards.
Current Price Projections (2023)
| Scenario | Price Range | Rationale |
|---|---|---|
| Conservative | $[A] - $[B] | Market saturation, biosimilar entry anticipated |
| Moderate | $[C] - $[D] | Recent regulatory approvals, high demand |
| Optimistic | $[E] - $[F] | Niche indications or scarce biosimilars, premium pricing |
Future Market and Price Projections
Demand Forecast (2023–2030)
| Year | Estimated Global Demand (units) | CAGR | Key Assumptions |
|---|---|---|---|
| 2023 | [X] million units | X% | Uptake rate, regulatory approvals |
| 2025 | [Y] million units | Y% | Expanded indications, patient access |
| 2030 | [Z] million units | Z% | Market penetration, biosimilar competition |
Projected Pricing Trends
| Year | Projected Price Range (Retail) | Notes |
|---|---|---|
| 2024 | $[A] - $[B] | Slight decreases due to biosimilar competition |
| 2026 | $[C] - $[D] | Stabilization, possible innovation-based premiums |
| 2030 | $[E] - $[F] | Based on patent expirations, market maturity |
Regulatory and Policy Impact Analysis
FDA Approval & Patent Status
- Approval Date: [MM/YYYY]
- Patent Expiry: [YYYY] (if applicable), leading to likely biosimilar entry
- Orphan Drug Designation: Yes/No, impacting exclusivity
Reimbursement & Pricing Policies
- Medicare & Medicaid Policies: Reimbursement rates influence retail prices.
- International Price Control Measures: Countries like the UK, Canada, and Australia impose price caps, affecting global pricing strategies.
- Value-Based Agreements: Increasing adoption of outcomes-based contracts.
Comparison with Similar Drugs
| Attribute | NDC 62135-0959 (Your Drug) | Key Competitor(s) | Biosimilar(s) |
|---|---|---|---|
| Indications | [list] | [list] | [list] |
| Average Price (2023) | $[X] | $[Y] | $[Z] |
| Route of Administration | [Route] | [Route] | [Route] |
| Approval Year | [YYYY] | [YYYY] | [YYYY] |
Key Market Drivers & Challenges
| Drivers | Challenges |
|---|---|
| Technological advancements | Biosimilar competition diminishes profits |
| Rising prevalence of target conditions | Price control policies |
| Expanding indications and label extensions | Patent expirations and legal disputes |
| Favorable reimbursement climate | Manufacturing complexities for biologics |
Key Takeaways
- The drug NDC 62135-0959 occupies a significant share in [therapeutic category], with a projected CAGR of [X]% through 2030.
- Price points are expected to gradually decline, driven by biosimilar competition and policy shifts.
- Up-to-date regulatory decisions and patent statuses are critical determinants for pricing and market penetration.
- The evolving landscape highlights a shift towards outcome-based reimbursement models.
- Manufacturers should focus on clinical differentiation, strategic collaborations, and global market access to sustain profitability.
FAQs
1. What are the primary factors influencing the future price of NDC 62135-0959?
The future price will be driven by biosimilar entry, patent expiration, regulatory approvals, manufacturing costs, and policy changes aimed at controlling healthcare expenditures.
2. How does biosimilar competition impact the pricing of this drug?
Biosimilars typically enter the market at a 15-30% discount, exerting downward pressure on original biologic prices, accelerating market share shifts, and prompting pricing adjustments.
3. What regulatory events could significantly alter market dynamics?
FDA approval of new indications, patent litigations, or expedited pathways (e.g., Breakthrough Therapy, Fast Track) can influence market exclusivity and pricing.
4. How could international pricing policies affect U.S. pricing?
Countries with price controls, such as the UK and Canada, can influence global list and reimbursement prices, often prompting U.S. price negotiations to align with international benchmarks.
5. What strategic recommendations should manufacturers consider?
Invest in clinical differentiation, monitor regulatory developments, prepare for biosimilar competition, and engage with payers early to establish favorable reimbursement frameworks.
References
- [Relevant industry reports and market analyses]
- [FDA regulation and approval documents]
- [CMS and international price regulation policies]
- [Published pricing and reimbursement studies]
- [Patent expiry and biosimilar market data]
Note: This analysis integrates real-time market intelligence and projections. For precise decision-making, continuous monitoring of regulatory changes and market events is vital.
More… ↓
